TREM2 and Parkinson disease: TREM2 inhibited NF-κB and MAPK signaling activation mediated by toll-like receptor4 (TLR4) and tumor necrosis factor receptor-associated factor 6 (TRAF6) in MPTP-induced mice PD models, reducing MPTP-induced neuropathic changes [17].